Structural optimization of pyrazolo[1,5-a]pyrimidine derivatives as potent and highly selective DPP-4 inhibitors

Drug discovery approaches targeting the incretin pathway

(2020) Xinxian Deng et al.   BIOORGANIC CHEMISTRY

Discovery of a Natural-Product-Derived Preclinical Candidate for Once-Weekly Treatment of Type 2 Diabetes

(2019) Shiliang Li et al.   JOURNAL OF MEDICINAL CHEMISTRY

SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials

(2018) Robert Puckrin et al.   ACTA DIABETOLOGICA

Surrogating and redirection of pyrazolo[1,5- a ]pyrimidin-7(4 H )-one core, a novel class of potent and selective DPP-4 inhibitors

(2018) Xinxian Deng et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Glucagon-Like Peptide-1 (GLP-1)-Based Therapeutics: Current Status and Future Opportunities beyond Type 2 Diabetes

(2018) Jia Ying Cheang et al.   ChemMedChem

Type 2 diabetes

(2017) Sudesna Chatterjee et al.   LANCET

Discovery and Rational Design of Natural-Product-Derived 2-Phenyl-3,4-dihydro-2H-benzo[f]chromen-3-amine Analogs as Novel and Potent Dipeptidyl Peptidase 4 (DPP-4) Inhibitors for the Treatment of Type 2 Diabetes

(2016) Shiliang Li et al.   JOURNAL OF MEDICINAL CHEMISTRY

DPP-4 inhibitors and cardiovascular disease in type 2 diabetes mellitus. Expectations, observations and perspectives

(2016) Enzo Bonora et al.   NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES

Synthesis and biological evaluation of triazole based uracil derivatives as novel DPP-4 inhibitors

(2016) Qing Li et al.   ORGANIC & BIOMOLECULAR CHEMISTRY

Discovery of Novel Tricyclic Heterocycles as Potent and Selective DPP-4 Inhibitors for the Treatment of Type 2 Diabetes

(2016) Wen-Lian Wu et al.   ACS Medicinal Chemistry Letters

Discovery of 3H-imidazo[4,5-c]quinolin-4(5H)-ones as potent and selective dipeptidyl peptidase IV (DPP-4) inhibitors: Use of a carboxylate prodrug to improve bioavailability

(2015) Yohei Ikuma et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Discovery of Imigliptin, a Novel Selective DPP-4 Inhibitor for the Treatment of Type 2 Diabetes

(2014) Chutian Shu et al.   ACS Medicinal Chemistry Letters

Novel tetrahydropyran analogs as dipeptidyl peptidase IV inhibitors: Profile of clinical candidate (2R,3S,5R)-2-(2,5-difluorophenyl)-5-[2-(methylsulfonyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl]tetrahydro-2H-pyran-3-amine (23)

(2013) Tesfaye Biftu et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Highly potent dipeptidyl peptidase IV inhibitors derived from Alogliptin through pharmacophore hybridization and lead optimization

(2013) Hui Xie et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

SYR-472, a novel once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor, in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial

(2013) Nobuya Inagaki et al.   Lancet Diabetes & Endocrinology